Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...

You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...

Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer ...

Biohaven Pharmaceuticals Inc. has presented preclinical data on their novel bispecific degrader BHV-1310 for the potential treatment of autoimmune disorders. To date, about 10% of the global ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

American Century Companies has boosted its stake in Biohaven (BHVN) by 9.5% during Q4, ETF Daily News reports, citing a recent SEC filing.The firm owned 558,761 shares of Biohaven after purchasing ...

Biohaven Ltd. has a one year low of $15.79 and a one year high of $55.70. The company’s fifty day moving average price is $28.43 and its 200 day moving average price is $38.46.

Biohaven (BHVN) announced that it will present 13 abstracts at the 2025 American Academy of Neurology, AAN, Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The ...